Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Genetic stability of recombinant MVA-BN.

Timm A, Enzinger C, Felder E, Chaplin P.

Vaccine. 2006 May 22;24(21):4618-21. Epub 2005 Aug 24.

PMID:
16157428
2.

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.

Sutter G, Staib C.

Curr Drug Targets Infect Disord. 2003 Sep;3(3):263-71. Review.

PMID:
14529359
3.

Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.

Rimmelzwaan GF, Sutter G.

Expert Rev Vaccines. 2009 Apr;8(4):447-54. doi: 10.1586/erv.09.4. Review.

PMID:
19348560
6.

Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.

Abaitua F, Rodríguez JR, Garzón A, Rodríguez D, Esteban M.

Virus Res. 2006 Mar;116(1-2):11-20. Epub 2005 Oct 7.

PMID:
16214252
7.

Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies.

Weyer J, Rupprecht CE, Mans J, Viljoen GJ, Nel LH.

Vaccine. 2007 May 22;25(21):4213-22. Epub 2007 Mar 22.

PMID:
17434244
8.

Transient host range selection for genetic engineering of modified vaccinia virus Ankara.

Staib C, Drexler I, Ohlmann M, Wintersperger S, Erfle V, Sutter G.

Biotechniques. 2000 Jun;28(6):1137-42, 1144-6, 1148.

PMID:
10868279
9.
11.

Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy.

Uberla K, Rosenwirth B, Ten Haaft P, Heeney J, Sutter G, Erfle V.

J Med Primatol. 2007 Feb;36(1):2-9.

PMID:
17359459
12.

Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'.

Chen Z, Huang Y, Zhao X, Ba L, Zhang W, Ho DD.

J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):412-21. doi: 10.1097/QAI.0b013e3181651bb2.

PMID:
18209682
13.

Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome.

Cottingham MG, Gilbert SC.

J Virol Methods. 2010 Sep;168(1-2):233-6. doi: 10.1016/j.jviromet.2010.04.012. Epub 2010 Apr 24.

PMID:
20417665
14.

[Construction of recombinant vaccinia virus expressing HSV-2 gD gene as live recombinant vaccine strain].

Yan H, Rong M, Ruan L, Hou Y, He N, Zhu J.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 1997 Mar;11(1):16-20. Chinese.

PMID:
15619895
16.

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

Gómez CE, Nájera JL, Jiménez EP, Jiménez V, Wagner R, Graf M, Frachette MJ, Liljeström P, Pantaleo G, Esteban M.

Vaccine. 2007 Apr 12;25(15):2863-85. Epub 2006 Oct 16.

PMID:
17113200
17.

Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences.

Smith KA, Stallard V, Roos JM, Hart C, Cormier N, Cohen LK, Roberts BE, Payne LG.

Vaccine. 1993;11(1):43-53.

PMID:
8427036
18.

Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine.

Liu J, Wyatt LS, Amara RR, Moss B, Robinson HL.

Vaccine. 2006 Apr 12;24(16):3332-9. Epub 2006 Jan 19.

PMID:
16472543
19.

Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene.

Laassri M, Meseda CA, Williams O, Merchlinsky M, Weir JP, Chumakov K.

J Med Virol. 2007 Jun;79(6):791-802.

PMID:
17457926
20.

Development of heat-stable recombinant rinderpest vaccine.

Tsukiyama K, Yoshikawa Y, Kamata H, Imaoka K, Asano K, Funahashi S, Maruyama T, Shida H, Sugimoto M, Yamanouchi K.

Arch Virol. 1989;107(3-4):225-35.

PMID:
2818208

Supplemental Content

Support Center